Evaluation of Geistlich Fibro-Gide® in Comparison to CTG for the Treatment Around Implants

Soft Tissue Defect Clinical Trial

Official title:

A Prospective, Randomized and Controlled Multi-center Study of Geistlich Fibro-Gide® Compared With Connective Tissue Graft for Soft Tissue Volume Augmentation Around Dental Implants

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04703738
• Other study ID #: 10808-122
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 13, 2018
• Est. completion date: December 2025

Study information

• Verified date: May 2021
• Source: Geistlich Pharma AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This double blind, randomized, parallel study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for soft tissue volume augmentation around dental implants

Description:

A total sample size of 60 subjects (n=60) will be evaluated at 5 centers, by 6 Investigators with approximately 10-subjects per Investigator. Power analysis based on 80% power, past Thoma, Zeltner and González-Martin studies 1,2,3 and a one-sided confidence interval of 0.025, indicates that with a volume change standard deviation between 0.5 and 0.7 mm, 17-31 subjects are required per group (test and control), so 50-60 subjects are an acceptable estimate, with a preference for 60, given potential loss to long-term follow-up.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: December 2025
• Est. primary completion date: June 21, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subjects requiring soft tissue augmentation around single implants, i.e., thin biotype with potential for

• All implants must be at least 6 months post bone graft/implant placement

• have at least 1 mm of keratinized tissue width (KTw),

• have final restoration permanently in place for at least 4-weeks and

• subject have no recession on the implant body

• Subjects who, can achieve good oral hygiene (80% plaque free surfaces on the implant and maintain 80% plaque free surfaces on teeth adjacent to treatment sites).

Exclusion Criteria:

• participation within the last six months in other interventional studies.

• any systemic condition that could influence healing, such as uncontrolled diabetes mellitus - confirmed by A1C score =7% - cancer, HIV, oral muco- cutaneous conditions and drug induced gingival enlargement.

• taking medications that compromise wound healing, such as chronic steroid use - either inhaler or systemic, calcium channel blockers with secondary hyperplastic tissue reactions, anti-seizure medications, IV bisphosphates for bone metabolic diseases, radiation or other immuno-suppressive therapy.

• acute infectious lesions in the areas intended for surgery.

• History within the last 6 months of weekly or more frequent use of nicotine products

• Female subjects who are pregnant or lactating, or sexually active female subjects who are of childbearing potential and who are not using hormonal or barrier methods of birth control

• Untreated, moderate to severe periodontal disease.

Related Conditions & MeSH terms

• Soft Tissue Defect

Intervention

Procedure:
• Soft tissue flap + Connective Tissue Graft
The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and graft without compression. The harvest graft donor area will be the palate in the bicuspid region on the same side as the control soft tissue augmentation therapy. The CTG will be harvested using full thickness incisions that include the periosteum and will be closed using suture and coating the incision line with a tissue adhesive. No covering stents or packs should be employed. The CTG will be sling sutured in place and the flap secured using a double sling suturing technique.

Device:
• Soft tissue flap + Geistlich Fibro-Gide®
The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and matrix without compression. Geistlich Fibro-Gide® is cut to shape to the treatment site and placed dry into the site. The flap is secured using a double sling suturing technique.

Locations

Country	Name	City	State
United States	McClain Schallhorn Periodonitcs	Aurora	Colorado
United States	Regenerative Solutions	Fullerton	California
United States	Perio Health Professionals	Houston	Texas
United States	Santarelli Oral and Facial Surgery	Kenosha	Wisconsin
United States	Periodontal and Dental Implant Surgical Specialist	Virginia Beach	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
Geistlich Pharma AG	Medelis Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in gingival soft tissue volume assessed with 3D scanning	Change in gingival soft tissue volume compared to baseline [Time Frame 6 months post-treatment] Measured by digital contour scan	6 months post treatment
Secondary	All Adverse Events, serious and non serious	Recording and Assessment of all (S)AEs starting from Visit 2 onwards, Surgery	Day 0, after 2, 4, 12weeks, 6 Months, 1,3,5 Years
Secondary	Post-OP Patient Reported Outcome Questionnaire	subjects will answer a questionnaire regarding discomfort, esthetic satisfaction and overall satisfaction questions asked by a 3rd-party rec; At Visits 2-weeks, and 1- and 3-months post-operative, subjects will answer discomfort/ pain questions asked by a 3rd-party recorder.	6 Months, 1,3,5 Years
Secondary	Concomitant medication	Concomitant medication review compared with Visit 1 and 2	2,4,12 weeks, 6 months, 1,3,5 Years
Secondary	Change in gingival soft tissue contour	soft tissue contour measured digitally ( 3D-scan) and compared with baseline	3 months, 1,3, 5 Years
Secondary	General Periodontal Examination (GPE)	Changes of GPE at various visits compared to baseline,	4, 12 weeks, 6 Months, 1,3,5 Years
Secondary	Pink esthetic score (PES)	pink esthetic score evaluates soft tissue around single-tooth implants. The PES is based on seven variables: Mesial papilla, Distal papilla, Soft tissue Level, Soft-tissue contour, Alveolar process deficiency, Soft-tissue Color, Soft tissue texture, 2-1-0 score	6 Months, 1,3,5 Years